All In Biotech

Drug Trial Radar · NCT03907852

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer

Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

57

Actual

Start

Apr 15, 2019

Primary completion

Nov 19, 2024

Study completion Nov 2, 2028

Sponsor

Lead sponsor
TCR2 TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Apr 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.

Conditions

  • Mesothelioma
  • Mesothelioma, Malignant
  • Mesothelioma; Pleura
  • Mesotheliomas Pleural
  • Mesothelioma Peritoneum
  • Cholangiocarcinoma
  • Cholangiocarcinoma Recurrent
  • Ovarian Cancer
  • Non Small Cell Lung Cancer
  • Non Small Cell Lung Cancer Metastatic
  • High Grade Ovarian Serous Adenocarcinoma

Interventions

  • gavo-celBiological

    gavo-cel

  • fludarabineDrug

    lymphodepletion chemotherapy

  • cyclophosphamideDrug

    lymphodepletion chemotherapy

  • NivolumabDrug

    immuno-oncology agent

  • IpilimumabDrug

    immuno-oncology agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1- Primary ObjectiveTime frame: DLTs within 28 days post-treatment
  2. Phase 2- Primary ObjectiveTime frame: ORR at 3 months; DCR based on ORR + SD lasting at least 8 weeks

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • University of Miami Sylvester Cancer Center

    Miami, Florida

  • University of Chicago Medical Center

    Chicago, Illinois

  • National Cancer Institute

    Bethesda, Maryland

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University

    Durham, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • SCRI Oncology Partners

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.